Avalyn Pharma(AVLN)今日盘中大涨44.44%，引起了市场的广泛关注。
消息面上，Avalyn Pharma是一家专注于开发治疗罕见呼吸系统疾病吸入式药物的生物技术公司，其于今日正式在纳斯达克全球精选市场挂牌交易。公司以每股18美元的价格发行1670万股股票，筹集了3亿美元资金，该定价位于此前发行区间上限，显示出市场对其的强烈兴趣。
本次IPO所得资金将主要用于推进公司核心候选药物AP01和AP02的后期临床研究。这两款药物分别为吡非尼酮和尼达尼布的吸入制剂，针对特发性肺纤维化等疾病，旨在提升疗效并减少副作用。公司此前已获得包括诺和诺德母公司Novo Holdings在内的顶级风投机构支持，此次成功上市为其从研发向商业化跨越提供了资金保障，也推动了股价在交易首日的大幅上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.